Center for Drug Evaluation and Research growing crisis around HIV testing and treatment and an inter-agency dispute between officials from the former Bureau of Drugs and officials from the former Bureau of Biologics over whether to approve Genentech's Activase (tissue plasminogen activator) led to the split. In its original form, CDER was composed of six offices: Management, Compliance, Drug Standards, Drug Evaluation I, Drug Evaluation II, Epidemiology and Biostatistics, and Research Resources. The Division of Antiviral Products was added in 1989 under Drug Evaluation II due to the large amount of drugs proposed for treating AIDS. The Office of Generic Drugs was also formed. In 2002,
S-Ethylisothiouronium diethylphosphate S-Ethylisothiouronium diethylphosphate "S"-Ethylisothiouronium diethylphosphate (brand name Difetur) is an "S"-alkylisothiouronium derivative used as an antihypotensive drug. The "S"-alkylisothiouronium compounds are used in processes of treating acute hypotension, which may result, for example, from shock or hemorrhage, and in processes for treating hyperoxic conditions, for example, oxygen poisoning. It is used for increasing arterial blood pressure in cases of acute arterial hypotension due to surgical interference, trauma, poisoning, shock condition,hemorrhages; in conjunction with epidural anesthesia; in overdose of ganglion blockers, alpha-adrenergic blockers, neuroleptics, anesthetics; and in other conditions when adrenomimetics are contra-indicated or ineffective. Difetur was also found to possess oxygen